Status:
COMPLETED
Interleukin-34 in Stage I and II Periodontitis
Lead Sponsor:
Ain Shams University
Conditions:
Cytokine Storm
Eligibility:
All Genders
20-50 years
Phase:
NA
Brief Summary
Interleukin 34 (IL-34) is the second active component of (colony-stimulating factor receptor) CSF-1R. With regards to periodontal disease, It is debatable whether IL-34 is a pro-inflammatory cytokine ...
Detailed Description
Periodontal disease is a multifactorial infection induced by a complex of bacterial species that interact with host tissues and cause destruction of the periodontal structures, including the supportin...
Eligibility Criteria
Inclusion
- Patients with stage I and II grade B Periodontitis in addition to periodontally healthy individuals.
- Both genders aged from 20-50 years
- Minimum 20 natural teeth excluding third molars.
- Good compliance with the plaque control instructions following initial therapy.
- Availability for follow-up and maintenance program.
Exclusion
- Smokers.
- Pregnant and lactating females.
- Systemic diseases that could affect the outcome of the therapy (According to the Cornell Medical Index-Health Questionnaire).
- Patients taking antibiotics, anti-inflammatory drugs, and immunosuppressive therapy during the preceding 6 months before the start of the trial and during the study.
- Patients who have undergone any periodontal therapy in the last 6 months.
- Vulnerable groups of patients' e.g. (handicapped patients).
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2023
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06052774
Start Date
January 1 2023
End Date
August 1 2023
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Dentistry-Ain Shams University
Cairo, Egypt